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Background: Oxidative stress and inﬂammation play an important role in the pathogenesis
of chronic obstructive pulmonary disease (COPD).
Objective: Pulmonary function, oxidative stress parameters and inﬂammatory markers
were measured in 74 patients with severe COPD exacerbation and 41 healthy subjects. In
patients all parameters were assessed at two time points: Firstly, one day after admission
and secondly, after 7–10 days when they were clinically stable enough to be discharged.
Patients were divided in two groups according the presence of ischemic heart disease
(IHD): IHD positive (IHD+) patients and IHD negative (IHD–) patients.
Methods and Results: During hospitalisation O2• –, malondialdehyde (MDA), advanced
oxidation protein products (AOPP) and total oxidant status (TOS) increased and were higher
at discharge compared with admission and the control group. Superoxide dismutase (SOD)
activity was signiﬁcantly lower in COPD patients at both time points compared with the
control group. Total antioxidant status (TAS) was signiﬁcantly lower and the prooxidant-
antioxidant balance (PAB) was higher at both time points in COPD patients compared with
the control group. High sensitive C-reactive protein (hsCRP) and also the neutrophil count
were signiﬁcantly higher at admission compared with discharge. Paraoxonase 1 (PON1)
enzymatic activities in COPD patients did not differ compared with the control group.
IHD+ COPD patients had signiﬁcantly lower PON1 activity but higher PAB levels and hsCRP
concentrations, compared with IHD– COPD patients.
Conclusion: The oxidant/antioxidant imbalance was signiﬁcantly pronounced in patients
with COPD exacerbation for at least 24 hours following their admission and when they were
clinically stable enough to be discharged. Increased oxidative stress, elevated systemic
inﬂammation and decreased antioxidant defence were common in end-stage disease and
particularly COPD patients with ischemic heart disease.
© 2011 Elsevier Ltd. All rights reserved.
Introduction
Chronic obstructive pulmonary disease (COPD) is a major
worldwide health disorder that has increasing prevalence,
morbidity and mortality. Neutrophils and macrophages may
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inﬁltrate into lung tissue thereby playing a key role
in the production of reactive oxygen species (ROS), in
augmenting inducible nitric oxide (NO) synthase expression
and the simultaneous production of superoxide (O2• –)
anions.1,2 Such hyperproduction of ROS leads to oxidative
damage of cell proteins, lipids, DNA and carbohydrates.
The oxidative stress contributes to irreversible damage of
both parenchyma and airway walls, activates molecular
mechanisms that initiate lung and systemic inﬂammation
and also to atherosclerosis.3,4
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Patients with reduced airﬂow have a signiﬁcantly higher
risk of death from myocardial infarction which is associated
with increased systemic oxidative stress, hypoxemia and
systemic inﬂammation observed in COPD patients.5–7
The aim of our study was to evaluate the relationship
between respiratory status, oxidative stress status and
inﬂammation in severe COPD exacerbation and during
treatment. We also analysed the possible independent
correlation between COPD exacerbation and parameters
of oxidative status and the relationship between ischemic
heart disease (IHD) and oxidative stress/inﬂammatory
markers in COPD exacerbation.
Methods
Study participants
Seventy four patients who presented with severe COPD
exacerbation were studied from March 2009 to September
2010. The control group included 41 healthy subjects
with no pulmonary, cardiovascular nor oncological disease,
inﬂammation, infection and neurological dysfunction that
could inﬂuence the oxidative status. COPD was deﬁned
according to the Global initiative for Chronic Obstructive
Lung Disease (GOLD) criteria.8 The severity of exacerbation
was categorized in items of clinical presentation and
healthcare resource utilization.9,10 The patients were
separated in two groups according to the presence of IHD.
Patients were excluded if they had lung cancer, known
psychiatric illness, maintenance treatment with systemic
corticosteroids, active tuberculosis or insulin-dependent
diabetes mellitus. The diagnosis of IHD was based on the
American College of Cardiology guidelines.11
The ﬁrst blood sample was taken from the patients within
24 hours of admission into the Clinic for Pulmonary Disease,
Clinical Centre of Serbia, Belgrade. Prior to admission,
the patients had only inhaled bronchodilator therapy in
the form of beta-2 agonists and/or ipratropium bromide.
Respiratory insufﬁciency was conﬁrmed if the arterial partial
oxygen pressure (PO2) was less than 8.0 kPa. All partici-
pants underwent a clinical and biochemical investigation
revealing age, gender and the assessment of risk factors
(including familial history of acute coronary disease, arterial
hypertension, smoking, dyslipidemia, current medication
and other socioeconomic variables). They were categorised
as current smokers, ex-smokers or non-smokers. Treatment
during the hospitalisation consisted of oxygen (1–2 L/min by
nasal prongs), nebulised beta-2 agonists and ipratropium,
theophylline, antibiotics and systemic corticosteroids.
The second blood sample was taken and pulmonary tests
performed 7–10 days later when the patient’s condition was
considered clinically stable enough for discharge.
The whole study was planned according to the ethical
standards detailed in the Declaration of Helsinki (as revised
in 1983). The local Institutional Ethics Committee approved
the research proposal and informed written consent was
taken from all patients.
Lung function
Spirometry was performed according to the ATS/ERS
standardisation guideline using a Master Scope spirometer
(Viasys Healthcare GmbH, Germany).12 Arterial blood




Plasma malondialdehyde (MDA) was measured using thio-
barbituric acid reagent; the rate of nitroblue tetrazolium
(NBT) reduction was used to measure the rate of superoxide
anion (O2• –) generation.13 Advanced oxidation protein
products (AOPP) were measured according to Witko-Sarsat
method and total oxidative status (TOS) according to Erel‘s
method.14,15
Antioxidative defence parameters
Plasma superoxide dismutase (SOD) activity was measured
according to a previously published method.16 The paraox-
onase 1 (PON1) status was assessed using a two-substrate
activity (paraoxon/diazoxon) method.16 Total antioxidant
capacity (TAS) was determined using an automated method
developed by Erel.15
Oxidant/antioxidant balance
The prooxidant-antioxidant balance (PAB) was measured
according to a previously published method.17
Inﬂammatory status
The concentration of hsCRP in serum was measured by latex-
enhanced immunoturbidimetry (Quantex hsCRP kit, BIOKIT,
Barcelona, Spain) using an ILAB 600 analyser. Neutrophil
number was determined by differential leukocyte counting
using an ABX Micros 60 analyser (Horiba Medical, Montpellier,
France).
Statistical analysis
All statistical analyses were performed using Medcalc
(MedCalc ver. 11.4 Software, Belgium). Data are shown
as mean ± standard deviation for normally distributed
variables, geometric mean and 95% conﬁdence interval for
log-normal values and as relative or absolute frequencies for
categorical variables. For analysis of categorical variables
we used the Chi-square test for contingency tables. A
comparison of continuous variables was performed by
independent t-test or ANOVA with Tukey’s post hoc test
for subgroup differences. To determinate possible corre-
lation between examined parameters Pearson’s correlation
analysis was employed. We used binary logistic regression
to analyse the possible independent association between
COPD exacerbation and parameters of oxidative status. The
control group was used as the reference group and was
coded 0, while the patients group was coded 1. Adjustment
analysis was performed to correct the inﬂuence of lipid
proﬁle risk factors (t-C, TG, LDL-C and HDL-C) and oxidative
stress status parameters (TAS, TOS).
Results
The general characteristics of the study groups are listed
in Table 1. They were matched by gender and by smoking
habits. COPD patients were signiﬁcantly older than the
control group (p < 0.001). To avoid the inﬂuence of age all
values for control subjects and patients were adjusted for
age prior to further statistical analyses.
The diagnosis of IHD was established in 33.8% of patients
and respiratory insufﬁciency in 38.5%.
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Table 1
Baseline characteristics by subject category.
Parameter COPD patients (n = 74) Healthy subjects (n = 41) p*
Sex, % W/M 57/43 61/39 ns
Age, years 63 (15) 42 (12) <0.01
BMI, kg/m2 24.4±5.32 26.0±5.11 0.062
Smoking habits, % never/ex/current 11/50/39 68/0/32 <0.01
Smoking pack-years 44.7±44.32 26.9±11.09 <0.01
Therapy, n NA
Long-acting bronchodilator, regularly 74
Inhaled corticosteroids, regularly 32
Short-acting bronchodilators, as needed 74
Comorbidities, n NA
Arterial hypertension 41
Diabetes mellitus type II 5
History of myocardial infarction 11
History of venous thromboembolism 4
Osteoporosis 5
Ischemic heart disease, % No/Yes 66/34 100.0/0.0 <0.001
Resting PaO2 below 8.0 kPa, % No/Yes 61.5/38.5 100/0.0 <0.001
Chi-square for categorical variables, Student’s t-test for continuous variables. ns: non-signiﬁcant.
BMI: body-mass index; NA: not applicable.
Table 2
Values of respiratory status, oxidative stress status and inﬂammatory markers in COPD patients vs. the control group
Parameter Control group Admission Discharge P
% predicted FEV1 NA 42.2±18.3 50.2±23.0 <0.001
FEV, L NA 1.12±0.66 1.32±0.82 <0.001
% predicted FVC NA 71.9±19.3 82.2±22.6 <0.001
FVC, L NA 2.23±0.9 2.62±1.10 <0.001
FEV1/FVC ratio NA 46.3±14.2 48.1±15.6 ns
PO2, kPa NA 7.49±1.44 8.68±1.97 <0.001
PCO2, kPa NA 5.81±1.16 5.88±1.24 ns
MDA, mmol/L 1.07±0.36 0.94±0.327 1.60±0.23**,aa <0.001
O2• –, mmol/L 43.58±19.1 97.2±26.4*** 100.6±23.4*** <0.001
AOPP, mmol/L 22.± 5 55±15*** 59±21*** <0.001
SOD, IU/L 118±46 20±8*** 19±6*** <0.001
POase, IU/L 330±216 417±324 447±374 ns
DZOase, IU/L 9618±3070 11134±3961 11549±4183 0.079
TAS, mmol/L 0.815±0.14 0.74±0.21 0.685±0.14** <0.01
TOS, mmol/L 2.68±1.64 3.02±2.46 5.74±4.60**,a <0.01
PAB, arb. U 72±22 144±43*** 126±45***,a <0.001
hsCRP, mg/L 0.90 (0.68–1.00) 5.46(3.63–8.20)*** 1.90(1.16–3.14)a aa <0.001
Neutrophiles, % 54.7±5.8 76.8±9.1*** 65.2±4.6***aa <0.001
Data are presented as mean±standard deviation except for CRP geometric mean (95%CI). P from Student’s t test for respiratory
parameters, for other parameters P from ANOVA test with Tukey’s post hoc test:
*p < 0.05, **p < 0.01, ***p < 0.001 vs. control group; a p < 0.05, aa p < 0.01 vs. admission. ns: non-signiﬁcant.
FEV1: Forced Expiratory Volume in the ﬁrst second; FVC: Forced Vital Capacity, MDA: malondialdehyde; NA: not applicable;
O2• –: superoxide anion; AOPP: advanced oxidation protein products; SOD-superoxide dismutase; POase: paraoxonase PON1 activity;
DZOase: diazoxonase PON1 activity; TAS: total antioxidant defence; TOS: total oxidant status; PAB: prooxidative–antioxidative balance;
hsCRP: high sensitivity C-reactive protein.
Pulmonary function, oxidative stress parameters and
inﬂammatory markers at admission and discharge are shown
in Table 2.
Oxidative stress status markers indicated free radical
generation during the course of COPD exacerbation.
The level of O2• – was signiﬁcantly higher in patients
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Table 3




PAB unadjusteda 1.073 (1.038–1.109)*** 1.042 (1.021–1.063)***
PAB adjusted:
Model 1 1.076 (1.035–1.120)*** 1.066 (1.029–1.104)***
Model 2 1.055 (1.017–1.095)* 1.030 (1.027–1.107)p = 0.062
Model 3 1.072 (1.002–1.149)* 0.000 (0.000–0.001)ns
a OR (95%CI): odds ratio (95% conﬁdence interval); *P< 0.05, ***P< 0.001, ns: non-signiﬁcant.
Model 1: adjusted for t-C, TG, LDL-C and HDL-C.
Model 2: adjusted for TAS, TOS.
Model 3: adjusted for t-C, TG, LDL-C, HDL-C, TAS and TOS.
Table 4
Inﬂuence of ischemic heart disease (IHD) presence on values of oxidative status markers.





FEV1, % 42.1±3.1 51.7±3.6 42.2±4.2 47.9±4.5 <0.01
PO2, kPa 7.51±0.3 8.85±0.3 7.46±0.3 8.42±0.4 ns
POase, IU/L 459±68 548±72 198±143 312±134 <0.05
PAB, HKU 139±7 125±8 152±13 121±12 ns
hsCRP, mg/L 5.40 (3.3–8.9) 1.89 (1.0–3.6) 5.55 (2.6–11.8) 1.94 (0.8–4.5) ns
Neutrophils % 73.5±2.1 64.7±2.6 75.7±3.0 66.3±3.9 0.082
Data are presented as mean ± standard deviation except for CRP median (25th-75th percentiles). p: Two-way ANOVA;
ns: non-signiﬁcant. FEV1: Forced Expiratory Volume in the ﬁrst second; POase: paraoxonase PON1 activity; PAB: prooxidative–
antioxidative balance, hsCRP: high sensitivity C-reactive protein.
compared with the control group. At discharge the
patients had signiﬁcantly higher levels of the oxidative
stress marker, MDA, compared to admission (p < 0.001).
In addition, serum AOPP concentrations paralleled those
of MDA concentrations. No signiﬁcant difference in POase
and DZOase activities between patients and controls was
noted (p = 0.119 and p = 0.079, respectively). The patients’
PON1 activities were higher at discharge compared with
admission, although the difference was not statistically
signiﬁcant.
The patients had signiﬁcantly higher TOS concentrations
(p < 0.001) and signiﬁcantly lower TAS concentrations
(p < 0.001) compared with the controls. PAB levels were
higher in patients compared to controls, both at the point of
admission and at discharge. The difference in PAB values at
the point of admission and at discharge was not statistically
signiﬁcant, although slightly lower at discharge.
Logistic regression models were constructed in order to
test the potential independent association of the analysed
oxidative stress status parameters and COPD status in
patients on admission and discharge. The best uni-variant
disease predictor was PAB concentration. Subsequent multi-
variant logistic regression analysis was performed on this
parameter (Table 3). The models incorporated adjustments
for lipid proﬁle parameters (Model 1), adjustments for
the general oxidative stress status parameters (Model 2)
and for all parameters included in analysis (Model 3).
The association between the PAB concentrations and COPD
status remained strong regardless of the confounding
variable at admission. It proved itself to be independently
associated with acute COPD exacerbation before the
treatment (Table 3). In contrast, the observed association
was lost after taking into account other investigated
parameters (Model 2 and Model 3) in patients at discharge
(Table 4).
Inﬂammatory markers (hsCRP and the percentage of
neutrophils) were signiﬁcantly higher in COPD than controls.
The hsCRP concentrations (p < 0.001) and neutrophil count
decreased on discharge (p < 0.01). Signiﬁcant positive
correlation was found between PAB and hsCRP suggesting
a possible relationship between oxidative stress and inﬂam-
mation (Pearson’s correlation r = 0.388, p < 0.05, Fig. 1).
In order to determine any additional inﬂuence of
previously diagnosed IHD on COPD outcome we sub-divided
our patients according to IHD+ and IHD–. The patients’
respiratory status parameters showed no differences
between IHD+ and IHD– at admission, but FEV1 was higher
in IHD+ patients on discharge (Table 4). The presence
of hypoxemia was noticed in all patients at admission
but oxygen saturation signiﬁcantly improved only in IHD–
patients after one-week of treatment.
Patients with IHD had signiﬁcantly lower POase activity
compared with IHD– patients, both at the time of admission
and at discharge (Table 4). IHD+ patients had higher PAB
values at the time of admission. Furthermore, IHD+ patients
had a tendency to develop more inﬂammation that was
documented by slightly higher hsCRP and the percentage
of neutrophils.
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Fig. 1. Pearson’s correlation graph between hsCRP and PAB.
Discussion
In this study we assessed changes in respiratory function,
oxidative stress and inﬂammatory status in patients with
severe COPD exacerbation from their hospital admission to
discharge.
All respiratory status markers were signiﬁcantly improved
at discharge compared with those at admission, but were
still lower than reference values (Table 1).
Oxidative stress was evident as revealed by O2• –, MDA,
AOPP and TOS. Oxidative stress plays a key role in the
pathogenesis and progression of COPD.18 ROS may contribute
to the pathophysiology of COPD in several ways. It is
well-known that increased ROS concentrations also activate
speciﬁc “stress sensitive” signalling pathways leading to
activation of the transcription factor NF-úB and as a result
the transcription of many inﬂammatory genes increases.4
The levels of hydrogen peroxide in patients with COPD,
particularly in a state of exacerbation, are higher than those
in healthy subjects.19 Such a huge increase in hydrogen
peroxide levels could be explained by a consequence of
large scale release of O2• – by alveolar neutrophils. Moreover,
we predict that SOD dismutated O2• – which probably
leads to hydrogen peroxide generation. The level of O2• –
rose during the whole period of patients’ monitoring in
our current study, which conﬁrmed previously published
data.20,21 Increased release of O2• – continued during the
next 7–10 days of hospitalisation, leading to increased
lipid peroxidation, assessed through the level of MDA,
an end product of lipid peroxide degradation (Table 2).
COPD patients show increased levels of lipid peroxidation
products such as F2-isoprostanes, 4-hydroxynonenal and
MDA, especially during exacerbation.22,23 Herein, MDA serum
concentrations were initially similar to those in healthy
subjects, but then rose signiﬁcantly until discharge. TOS
values increased constantly during hospitalisation and were
proportional to other oxidative stress markers, which could
imply general oxidative stress ﬂuctuations of other measured
markers. Plasma SOD activity in patients with COPD was
signiﬁcantly lower compared to healthy subjects. This fact
can be explained by sustained increased levels of O2• – in
COPD patients which were also noted by Rahman et al.20
As a result the antioxidant defence system is exhausted.
A decrease in antioxidant defence was conﬁrmed by lower
TAS levels in our COPD patients. Rahman et al. measured
changes in TAS values in COPD patients from the point of
exacerbation to discharge as in our study, but instead they
found elevated TAS values (opposite to our results).22 This
could be explained by different therapeutic approaches.
The above-mentioned study included patients treated with
corticosteroids for a week before admission to hospital; we
examined only previously untreated patients. Speciﬁcally,
the TAS values in our patients decreased during the period
between the two measurements. Furthermore, we measured
the PAB level as a marker of total oxidation status. According
to our knowledge, this marker has never been used before to
reveal the oxidative status of COPD patients. The PAB levels
were signiﬁcantly higher in patients compared to controls,
suggesting pro-oxidant prevalence.
The most important matter that we addressed here
was the potential application of parameters of oxidative
stress status determination for COPD patients’ assessment.
Our aim was to examine if any of these parameters
could be independently associated with acute non-treated
COPD exacerbation. To gain insight into this feature we
calculated odds ratios (ORs) for parameters of oxidative
stress status. We found that the level of PAB was potentially
the strongest indicator of COPD exacerbation existence
(Table 3). Moreover, the association between PAB and COPD
exacerbation remained signiﬁcant even after adjustment for
lipid proﬁle and for other oxidative stress status parameters
(Table 3). This suggests possible involvement of oxidative
stress in COPD pathogenesis. In addition, it is interesting,
that the association of PAB and COPD was lost at the time of
patient discharge (Table 4). There was a signiﬁcant decrease
in the PAB level at discharge compared with admission. This
resulted in the loss of PAB’s predictive potential for COPD
patient separation from control subjects (Table 4). These
results directly show the beneﬁt of implemented therapy on
oxidative stress status in COPD patients.
Oxidative stress may also be a mechanism to enhance
lung inﬂammation that is a characteristic feature of COPD.
Lipid peroxidation products can act as signalling molecules
and cause the release of inﬂammatory mediators from
lung cells. The release of these inﬂammatory mediators
is associated with increased expression of genes encoding
other inﬂammatory mediators. Therefore, inﬂammation
which itself drives higher oxidative stress production,
creates a vicious circle of enhanced inﬂammation resulting
from increased oxidative stress.18 Increased systemic
inﬂammation in our patients was evident through increased
levels of hsCRP. CRP is a biomarker of systemic inﬂammation
but also a marker of increased cardiovascular risk.21
Links between oxidative stress and inﬂammation were
documented by positive correlation between PAB levels and
hsCRP concentrations in COPD patients on admission in
acute exacerbation (Fig. 1). Positive correlation between
neutrophil count and hsCRP suggested a connection between
the main source of ROS and inﬂammation.
The presence of cardiovascular disturbances in patients
with COPD is no coincidence.21 There are data that suggest
that factors such as systemic inﬂammation, oxidative stress,
hypoxemia, cachexia, endothelial dysfunction and even
aging could also be involved.21,24–26 Approximately 25% of
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patients with COPD die from cardiovascular disease.24 Our
results indicated increased systemic inﬂammation through
elevated hsCRP in both groups (IHD+ and IHD–), slightly
higher in IHD+ COPD patients. The oxidative stress status
in COPD patients with IHD indicated an oxidant/antioxidant
imbalance. Namely, PAB levels in those patients were more
elevated than in IHD– patients. Alamdari et al. already
considered PAB as a new cardiovascular risk factor.17 Higher
PAB, as a measure of oxidative imbalance, indicates that
IHD+ patients have a tendency to develop greater oxidative
stress compared with IHD– patients. Previous studies showed
a decrease in PON1 activity in patients with asthma during
exacerbation and a decrease in PON1 gene expression during
development of COPD symptoms.27,28 PON1 activities in our
COPD patients were slightly higher than in control subjects.
However, POase PON1 activity in IHD+ COPD patients was
signiﬁcantly lower comparing to IHD– patients, especially
at the point of admission after exacerbation (Table 4).
Our previous study suggested a role for decreased PON1
activity in coronary artery disease development.16 PON1
activity in IHD+ patients at the time of admission was similar
to that of PON1 activity in three end-stage COPD disease
patients who later died (results are not shown because
of the small number of deceased patients). According to
this result we could speculate that lower PON1 activities
could be connected with increased risk of death in COPD.
COPD and chronic heart failure are both chronic diseases
which activate similar responses and also share similarities
with chronic inﬂammation.25,26 This could explain gradual
ischemic heart disease development during the course of
COPD.
Limitations of our current study: Our conclusions are
based upon results from a cross-sectional study and some
of the aims could have been better addressed in a
prospective study with more studied subjects. Our study
included a relatively small number of participants because
patients with severe COPD exacerbation are usually treated
with antibiotics and systemic steroids before admission to
hospital, which therefore prevents them from being part of
this study. We wanted to exclude the inﬂuence of such drugs
on oxidative status. We plan to include new COPD patients
and follow them whilst in a stable state one month after the
acute exacerbation event.
Conclusion
Our data add further support to the concept of
oxidative-stress-induced increase in COPD exacerbations.
The oxidant/antioxidant imbalance was signiﬁcantly pro-
nounced in patients with COPD exacerbation, most markedly
at admission. Oxidative stress damage was greater at
discharge than the admission, most likely due to poor and/or
limited antioxidant defence. A persistently decreased
antioxidant capacity was seen in the plasma of patients
with an acute exacerbation of COPD for at least 24 hours
following their admission, with a rise at the end of the
exacerbation when they were considered to be clinically
stable enough for discharge. Also, it is important to
notice that for the ﬁrst time PAB was demonstrated as a
marker of oxidative stress which is associated with COPD
exacerbation and could be modulated by medical treatment.
Simultaneous systemic inﬂammation was also evident in
COPD exacerbation. Increased oxidative stress, elevated
systemic inﬂammation and decreased antioxidant defence
were common in end-stage disease and COPD patients with
ischemic heart disease.
Future studies should consider development of novel
therapeutic interventions with antioxidant therapy as
adjunct therapy for COPD exacerbation.
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